New generation of antidepressants in pregnant women
AbstractAlthough pregnancy was once thought to protect against psychiatric disorders, gravid and non gravid women have similar risks for major depression, at 10% to 15%. Both depression and antidepressant treatment during pregnancy have been associated with risks. Few medications have been proved unequivocally safe during pregnancy. Although certain antidepressants have not been linked with an increased risk of birth defects or impaired development including bupropion, citalopram, escitalopram and venlafaxine, the latest studies aren't necessarily reassuring. As researchers continue to learn more about antidepressants, the risks and benefits of taking the drugs during pregnancy must be weighed carefully on a case-by-case basis. This review discusses about the use of new generation of antidepressants in pregnancy
-Kessler RC, McGonagle KA, Swartz M, Blazer DG, Nelson CB. Sex and depression in the National Comorbidity Survey I: Lifetime prevalence, chronicity and recurrence. J Affect Dis 1993; 29: 85-96.
-Akhondzadeh S, Faraji H, Sadeghi M, Afkham K, Fakhrzadeh H, Kamalipour A. Double blind comparison of fluoxetine and nortriptyline in the treatment of moderate to severe major depression. J Clin Pharmacy Therapeutics 2003; 28: 379-384.
-Bennett HA, Einarson A, Taddio A, Koren G, Einarson TR. Prevalence of depression during pregnancy: systematic review. Obstet Gynecol 2004; 103: 698-709.
-Bonari L, Pinto N, Ahn E, Einarson A, Steiner M, Koren G. Perinatal risks of untreated depression during pregnancy. Can J Psychiatry 2004; 49: 726-735.
-Zuckerman B, Amaro H, Bauchner H, Cabral H. Depressive symptoms during pregnancy: relationship to poor health behaviors. Am J Obstet Gynecol 1989; 160: 1107-1111.
-Bolton HL, Hughes PM, Turton P, Sedgwick P. Incidence and demographic correlates of depressive symptoms during pregnancy in an inner London population. J Psychosom Obstet Gynaecol 1998; 19: 202-209.
-Forest Laboratories. Product information 2005.
-Heikkinen T, Ekblad U, Kero P, Ekblad S, Laine K. Citalopram in pregnancy and lactation. Clin Pharmacol Ther 2002; 72: 184-191.
-Ericson A, Kallen B, Wiholm B. Delivery outcome after the use of antidepressants in early pregnancy. Br J Clin Pharmacol 1999; 55: 503-508.
-Nordeng H, Lindemann R, Perminov KV, Reikvam A. Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors. Acta Paediatr 2001; 90: 288-291.
-Laine K, Heikkinen T, Ekblad U, Kero P. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiarty 2003; 60:720-726.
-Tucker WE Jr. Preclinical toxicology of bupropion: An overview. J Clin Psychiatry 1983; 44: 60-62.
-GlaxoSmithKline Bupropion Pregnancy Registry. Research Triangle Park, NC 2004.
- Chun-Fai-Chan B, Koren G, Fayez I, Kalra S, Voyer-Lavigne S, Boshier A. Pregnancy outcome of women exposed to bupropion during pregnancy: A prospective comparative study. Am J Obstet Gynecol 2005; 192: 932-936.
-da-Silva VA, Altenburg SP, Malheiros LR, Thomaz TG, Lindsey CJ. Postnatal development of rats exposed to fluoxetine or venlafaxine during the third week of pregnancy. Braz J Med Biol Res 1999; 32: 93-98.
-Einarson A, Fatoye B, Sarkar M, Lavigne SV, Brochu J, Chambers C. Pregnancy outcome following gestation exposure to venlafaxine: a multicenter prospective controlled study. Am J Psychiarty 2001; 158:1728-1730.
-Sanz EJ, De-las-Cuevas C, Kiuru A, Bate A, Edwards R. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet 2005; 365: 482-487.
-de Moor RA, Mourad L, ter Haar J, Egberts AC. Withdrawal symptoms in a neonate following exposure to venlafaxine during pregnancy. Ned Tijdschr Geneeskd 2003; 12:1370-1372.
-Neonatal complications after intrauterine exposure to SSRI antidepressants. Prescrire Int 2004;13:103-104.